Pfizer
Djork-Arné Clevert has extensive experience in the field of machine learning research and its application to various industries. Djork-Arné currently serves as the Vice President and Head of Machine Learning Research at Pfizer, a role they have held since 2022. Prior to this, they were the Head of Machine Learning Research, Director, and Senior Research Fellow at Bayer Pharmaceuticals from 2019 to 2022. Djork-Arné also worked as a Senior Research Scientist at Bayer Pharmaceuticals from 2015 to 2019.
In addition to their industry experience, Djork-Arné Clevert has also been involved in several research projects. Djork-Arné served as a Principal Investigator for Explainable AI for Molecules - AiChemist MSCA DN Horizon Europe, where they focused on optimizing biological activity and ADME properties while minimizing toxicity using advanced machine learning methods. Djork-Arné was also a Principal Investigator for the AIDD-ITN project, which aimed to train and prepare a new generation of scientists skilled in both machine learning and chemistry to advance medicinal chemistry.
Djork-Arné Clevert has also been involved in various co-Principal Investigator roles. Djork-Arné was part of the OPTIMA Oncology project, which aimed to revolutionize oncology care in Europe through shared decision-making based on computer-interpretable guidelines and AI-driven technology. Djork-Arné was also involved in the ONTOX and Bigpicture projects, as well as the MELLODDY consortium, which aimed to enhance predictive machine learning models in drug discovery.
Before their industry and research roles, Djork-Arné Clevert worked as a Senior Data Scientist at Zalando AG and as a Post-Doctoral Researcher and Marie Curie Fellow at Johannes Kepler University.
Overall, Djork-Arné Clevert has a strong background in machine learning research and its application to various industries, particularly in the pharmaceutical and chemical fields. Djork-Arné has demonstrated expertise in optimizing biological activity and developing predictive models while ensuring explainability and minimizing toxicity.
Djork-Arné Clevert has a diverse educational background. Djork-Arné completed their Prediploma in Process Sciences and Engineering and Prediploma in Computer Science at Technische Universität Berlin. Djork-Arné then went on to earn their Diploma (M.Sc) in Computer Science from the same institution. Djork-Arné pursued further studies at Charité - Universitätsmedizin Berlin and obtained a Doctor of Philosophy (Ph.D.) in Computational Biology. Additionally, they attended Johannes Kepler Universität Linz, where they focused on Bioinformatics and Machine Learning. Djork-Arné Clevert also participated in a program at MIT Sloan School of Management, specializing in Digital Innovation and R&D Tech Immersion in 2017.
This person is not in any teams
This person is not in any offices
Pfizer
614 followers
Pfizer Inc. is a research-based, global biopharmaceutical company. They apply science and their global resources to bring therapies to people that extend and significantly improve their lives through the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. They work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Pfizer collaborates with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world. Pfizer was founded in 1942. Most of Pfizer’s revenues come from the manufacture and sale of biopharmaceutical products. They believe that their medicines and vaccines provide significant value for healthcare providers and patients, through improved treatment of diseases, improvements in health, wellness and productivity as well as by reducing other healthcare costs, such as emergency room or hospitalization. Pfizer is committed to fulfilling their purpose: Breakthroughs that change patients’ lives. Their purpose fuels everything they do and reflects both their passion for science and commitment to patients. Pfizer’s growth strategy is driven by five “Bold Moves” that help them deliver breakthroughs for patients and create value for shareholders and other stakeholders: 1. Unleash the power of our people; 2. Deliver first-in-class science; 3. Transform our go-to-market model; 4. Win the digital race in pharma; and 5. Lead the conversation.